000			02251cam a2200349 a 4500
003			EG-GiCUC
005			20250223032433.0
008			191109s2019 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.08.M.Sc.2019.Ah.E
100	0		_aAhmed Mohamed Abdelbaky
245	1	4	_aThe effectiveness of insulin glargine in addition to basic treatment with regular insulin on recovery of patients with diabetic ketoacidosis compared to regular insulin alone / _cAhmed Mohamed Abdelbaky ; Supervised Ahmed Mowafy , Khaled Zein Eldeen , Amr Nawar
246	1	5	_aدراسة فعالية اضافة إنسولين الغلارجين إلي الإنسولين المائي علي تعافي مرضي الحماض الكيتوني السكري مقارنة باستعمال الإنسولين المائي فقط
260			_aCairo : _bAhmed Mohamed Abdelbaky , _c2019
300			_a83 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine- Department of Critical Care Medicine
520			_aDiabetic Ketoacidosis (DKA) is a potentially fatal metabolic disorder presenting as a common cause of intensive care unit admission. The disorder can have significant mortality if misdiagnosed or mistreated. The main features of DKA are hyperglycemia, metabolic acidosis with a high anion gap and heavy ketonuria. Insulin Glargin is along-acting basal insulin analogue shows no plasma insulin peaks. Insulin glargin was reported to be safe and effective to be added to the standard protocols of DKA management giving the advantage of reducing time of recovery of DKA patients and facilitate the transition from intravenous insulin infusion to subcutaneous injection, with no increase in risks of hypoglycemia, nor hypokalemia
530			_aIssued also as CD
653		4	_aDiabetic Ketoacidosis (DKA)
653		4	_aInsulin glargine
653		4	_aKetonuria
700	0		_aAhmed Mowafy , _eSupervisor
700	0		_aAmr Nawar , _eSupervisor
700	0		_aKhaled Zein Eldeen , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c75050 _d75050